Kindred Biosciences, Inc. (KIN) financial statements (2021 and earlier)

Company profile

Business Address 1555 BAYSHORE HIGHWAY, SUITE 200
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:7474835773101
Cash and cash equivalents16563572013
Short-term investments561846505388
Other undisclosed cash, cash equivalents, and short-term investments2(0)1   
Receivables11    
Inventory, net of allowances, customer advances and progress billings44    
Inventory44    
Other undisclosed current assets12(1)110
Total current assets:7980825874102
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment30267210
Long-term investments and receivables2 115 
Long-term investments2 115 
Other noncurrent assets000000
Total noncurrent assets:35269460
TOTAL ASSETS:114106916280102
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10156433
Accounts payable141010
Accrued liabilities482211
Employee-related liabilities433221
Debt1     
Total current liabilities:10156433
Noncurrent Liabilities
Long-term debt and lease obligation22     
Long-term debt, excluding current maturities19     
Operating lease, liability3
Liabilities, other than long-term debt 00000
Accounts payable and accrued liabilities 00000
Total noncurrent liabilities:2200000
Total liabilities:32156433
Stockholders' equity
Stockholders' equity attributable to parent, including:829185587699
Common stock000000
Additional paid in capital305253197139135131
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)
Accumulated deficit(223)(162)(112)(81)(59) 
Other undisclosed stockholders' equity attributable to parent     (31)
Total stockholders' equity:829185587699
TOTAL LIABILITIES AND EQUITY:114106916280102

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues42    
Cost of revenue
(Cost of Goods and Services Sold)
(1)(0)    
Gross profit:42    
Operating expenses(66)(53)(32)(23)(27)(27)
Other undisclosed operating income00    
Operating loss:(63)(51)(32)(23)(27)(27)
Nonoperating income
(Investment Income, Nonoperating)
121000
Net loss available to common stockholders, diluted:(61)(50)(31)(22)(27)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(61)(50)(31)(22)(27)(27)
Comprehensive loss:(61)(50)(31)(22)(27)(27)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00 0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(61)(50)(31)(22)(27)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: